PATENT CLAIM ANALYSIS

Application Number: 16163108
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "220000"]

Abstract:
A P2X 4  receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome: wherein R 1  is hydrogen, a C 1-8  alkyl group, or the like; each of R 2  and R 3  is hydrogen, a C 1-8  alkyl group, or the like; each of R 4  and R 5  is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.

Claim (Index 2):
A method according to  claim 1 , wherein the compound is 5-[3-(1H-tetrazol-5-yl)phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione potassium salt.

Metadata:
- Claim Count in Document: 18.0
- Percentile: 97.0
- Lexical Diversity: 1.71212
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14808609', '13882205', '13807387', '13811909', '13921382']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7925932450273908
- 35 USC 102 Novelty (BERT): 0.5112149481263996
- Combined Prediction Score: 0.7644554153372917
- Mean Citation Score: 278.42473800000005
- Max Citation Score: 287.89328
- Similarity Product: 213.70085767875668

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test